(Q34215904)

31 July 2017

1 reference

title

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond (English)

1 reference

31 July 2017

1 reference

1

Susana Banerjee

1 reference

31 July 2017

Stan Kaye

2

1 reference

31 July 2017

publication date

1 December 2011

1 reference

31 July 2017

published in

Current Oncology Reports

1 reference

31 July 2017

volume

13

1 reference

31 July 2017

issue

6

1 reference

31 July 2017

page(s)

442-449

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-011-0193-9

31 July 2017

exact match

0 references

cites work

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Involvement of Brca2 in DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0193-9

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

12 December 2020

Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34.

1 reference

12 December 2020

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

1 reference

12 December 2020

Making the best of PARP inhibitors in ovarian cancer

1 reference

12 December 2020

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

1 reference

12 December 2020

BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study

1 reference

12 December 2020

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

1 reference

12 December 2020

10.1007/S11912-011-0193-9

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1031333294

0 references

1 reference